Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 576 - 600 of 1421 in total
MUL001 is live attenuated strain of Salmonella typhimurium being investigated for the treatment of schwannomas.
Investigational
Investigational
AK106-001616 is under investigation in clinical trial NCT01285752 (A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)).
Investigational
Rivabazumab pegol is being investigated as a treatment of Pseudomonas aeruginosa lung infections in patients with cystic fibrosis.
Investigational
Saruparib is under investigation in clinical trial NCT06380751 (Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in Hr-positive, Her2-negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or Palb2m Advanced Breast Cancer).
Investigational
Matched Description: … With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in Hr-positive, Her2-negative (IHC 0, …
Investigational
Sepiapterin is under investigation in clinical trial NCT03519711 (A Study of CNSA-001 in Primary Tetrahydrobiopterin (BH4) Deficient Participants With Hyperphenylalaninemia).
Investigational
Matched Description: … Sepiapterin is under investigation in clinical trial NCT03519711 (A Study of CNSA-001 in Primary Tetrahydrobiopterin …
Quavonlimab is under investigation in clinical trial NCT03179436 (Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)).
Investigational
Matched Description: … Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001
Asvasiran is an siRNA that targets the respiratory syncytial virus (RSV) N gene and inhibits viral replication. It has the potential to treat or prevent RSV infection.
Investigational
Investigational
Axalimogene filolisbac is under investigation in clinical trial NCT02853604 (Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer).
Investigational
Matched Description: … Axalimogene filolisbac is under investigation in clinical trial NCT02853604 (Study of ADXS11-001 in Subjects …
MK-1064 is under investigation in clinical trial NCT02549014 (A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of MK-1064 (MK-1064-001)).
Investigational
Matched Description: … NCT02549014 (A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of MK-1064 (MK-1064-001
Fasoracetam is under investigation in clinical trial NCT03609619 (PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without Mglur Mutations).
Investigational
Matched Description: … Fasoracetam is under investigation in clinical trial NCT03609619 (PART B: Efficacy and Safety of AEVI-001
Ivarmacitinib (SHR0302) is a selective inhibitor of Janus kinase 1 (JAK1) under investigation for the treatment of various immuno-inflammatory conditions. While ivarmactinib has yet to receive marketing authorization, as of February 2022 clinical trials are ongoing or completed evaluating its use in atopic dermatitis,[L40604,L40619,L40629] ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis,...
Experimental
Investigational
Brogidirsen is under investigation in clinical trial NCT05996003 (NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)).
Investigational
Actoxumab is under investigation in clinical trial NCT01241552 (A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)).
Investigational
Matched Description: … MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001
Investigational
Investigational
Experimental
Withdrawn
MYO-029 is a human anti-GDF-8 monoclonal antibody, which is being developed to treat muscle-wasting diseases including muscular dystrophy and age-related sarcopenia.
Investigational
Investigational
Experimental
Withdrawn
MK-8777 is under investigation in clinical trial NCT00610649 (Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of Org 26576 in Participants With Major Depressive Disorder (174001/P05704/MK-8777-001)).
Investigational
Matched Description: … and Tolerability, of Org 26576 in Participants With Major Depressive Disorder (174001/P05704/MK-8777-001
U-0126 is a direct inhibitor of the mitogen-activated protein-kinase kinase family members, MEK-1 and MEK-2.
Investigational
Investigational
Displaying drugs 576 - 600 of 1421 in total